Sign inSubscribe

target directory

b cell malignancies clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT04170283
Source recordAI-normalized

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies

This long-term extension study evaluates the safety and efficacy of zanubrutinib (BGB-3111) in patients with B-cell malignancies who have previously participated in a parent study. The study aims to provide insights into the long-term effects and potential benefits of continued treatment with zanubrutinib, either alone or in combination with Tislelizumab.

AI analysis

Indication: B-cell Malignancies

Modality: monoclonal antibody

Target: B-cell Malignancies

Sponsor: BeiGene

Source URL: ClinicalTrials.gov

Source updated: Oct 21, 2025

Ingested: May 23, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: B-cell Malignancies

View original source fields

Condition raw: B-cell Malignancies

Condition normalized: B-cell Malignancies

Modality raw: B-cell Malignancies

Modality normalized: monoclonal antibody

Target raw: B-cell Malignancies

Target normalized: B-cell Malignancies

Open report